title: Oxidative protein damage with carbonyl levels and nitrotyrosine expression after chemotherapy in bone marrow transplantation patients.
abstract: Protein oxidation is defined as the covalent modification ofa protein, induced either directly by reactive oxygen species/reactive nitrogen species or indirectly by reaction with secondary by-products of oxidative stress. Protein carbonyls are the most commonly measured products of protein oxidation. Additionally, nitrotyrosine is a product of tyrosine nitration mediated by reactive nitrogen species such as peroxynitrite anion and nitrogen dioxide. Samples were collected before the preparative regimen (10 days before transplantation; day –10), on transplantation day (day 0), and after transplantation (days 7, 14, and 28) from 16 pediatric allogeneic hematopoietic stem cell transplantation (HSCT) patients.The erythrocyte 3-nitrotyrosine expression was shown to be significantly increased after chemotherapy. In accordance, the mean plasma carbonyl levels on days 14 and 28 were significantly higher than on the other days. High dose chemotherapy applied in the preparative regimen of HSCT may be responsible for this long-term oxidation of plasma proteins. These results show that high-dose chemotherapy resulted in protein oxidation both in plasma and in erythrocytes in HSCT patients.
authors.affiliation: Department of Pharmaceutical Toxicology, Faculty of Pharmacy, Hacettepe University, Sihhiye/Ankara, Turkey. suna@hacettepe.edu.tr
authors.forename: Suna
authors.initials: S
authors.lastname: Sabuncuoğlu
authors.forename: Yeşim
authors.initials: Y
authors.lastname: Öztaş
authors.forename: Duygu Uçkan
authors.initials: DU
authors.lastname: Çetinkaya
authors.forename: Nuriman
authors.initials: N
authors.lastname: Özgüneş
authors.forename: Hilal
authors.initials: H
authors.lastname: Özgüneş
mesh_terms: D000961:Antilymphocyte Serum / Q000008:administration & dosage; D018906:Antineoplastic Agents, Alkylating / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols; D016026:Bone Marrow Transplantation; D002066:Busulfan / Q000008:administration & dosage; D002648:Child; D002675:Child, Preschool; D003520:Cyclophosphamide / Q000008:administration & dosage; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage; D008297:Male; D008558:Melphalan / Q000008:administration & dosage; D010084:Oxidation-Reduction; D050050:Protein Carbonylation; D014443:Tyrosine / Q000031:analogs & derivatives / Q000097:blood
chemical_list: D000961:Antilymphocyte Serum; D018906:Antineoplastic Agents, Alkylating; D007166:Immunosuppressive Agents; C002744:3-nitrotyrosine; D014443:Tyrosine; D003520:Cyclophosphamide; D002066:Busulfan; D008558:Melphalan